カテゴリ： GlobalData, インド, 企業調査

Cadila Healthcare Ltd (CADILAHC)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Cadila Healthcare Ltd (CADILAHC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9939
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：71
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：インド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cadila Healthcare Ltd (Zydus Cadila) is an integrated, global healthcare provider. It discovers, develops, manufactures and markets various healthcare products. The company’s product portfolio includes active pharmaceutical ingredients (APIs), formulations, wellness and animal health products. Zydus Cadila’s products find application in the treatment of diseases in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women’s health, among others. It conducts research to develop biologics, vaccines and new chemical entities. The company has manufacturing facilities in Brazil and India. It has presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Cadila is headquartered in Ahmedabad, Gujarat, India.

Cadila Healthcare Ltd (CADILAHC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 14
Zydus Healthcare Acquires Six Brands from Merck 15
Zydus Cadila Healthcare Acquires Rights to Melgain from Issar Pharma 16
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 17
Zydus Cadila Healthcare to Acquire Actibile from Albert David for USD8.2 Million 18
Sentynl Therapeutics Acquires Abstral from Galena Biopharma 19
Private Equity 20
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 20
Partnerships 22
Zydus Cadila Healthcare to Enter into Agreement with Medicure International 22
Cadila Healthcare Enters into Agreement with Pharm Aid 23
Zydus Cadila Healthcare Enters into Agreement with Medicines for Malaria Venture 24
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 25
Zydus Cadila and Eczacibasi Enter into Agreement 26
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27
Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 28
IDRI And Zydus Cadila Healthcare Enter Into Agreement To Develop Vaccine Candidate For Visceral Leishmaniasis 30
Zydus Cadila On The Lookout For Partners To Market New Chemical Entity, Lipaglyn 31
Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 32
Licensing Agreements 33
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 33
Zydus Cadila Healthcare Enters into Licensing Agreement with Neovii Biotech 34
Zydus Cadila Healthcare Enters into Licensing Agreement with Medicines Patent Pool 35
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 36
Equity Offering 37
Cadila Healthcare to Raise Funds in Public Offering of Securities 37
Asset Transactions 38
Zydus Healthcare to Acquire India Human Formulations Undertaking from Cadila Healthcare for USD10.2 Million 38
Acquisition 39
Cadila Healthcare Acquires 51% Stake in Windlas Healthcare for USD22.5 Million 39
Zydus Cadila Healthcare Acquires Sentynl Therapeutics for USD171 Million 40
Zydus Cadila Healthcare To Sell Nippon Universal Pharma 41
Cadila Healthcare Ltd – Key Competitors 42
Cadila Healthcare Ltd – Key Employees 43
Cadila Healthcare Ltd – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 46
Recent Developments 48
Financial Announcements 48
May 25, 2018: Zydus Cadila’s Net Profit up by 53% in Q4 48
Feb 08, 2018: Zydus Cadila’s EBIDTA up by 108% in Q3 49
Feb 07, 2018: Zydus Wellness’ Consolidated Net profit up by 43.8% in Q3 50
Nov 14, 2017: Zydus Cadila’s EBIDTA up by 68% in Q2 51
May 27, 2017: Zydus Cadila registers Net Profit of Rs. 1488 crores in FY 17 52
Jan 31, 2017: Cadila Healthcare Announces Q3 results 53
Legal and Regulatory 54
Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium 54
Oct 04, 2018: Cadila Healthcare’s manufacturing facility Zydus Biologics receives an Establishment Inspection Report from USFDA 55
Aug 29, 2018: Zydus Cadila: Update on USFDA inspection of injectables manufacturing facility of Liva Pharmaceuticals 56
Aug 29, 2018: Cadila Healthcare intimates of USFDA inspection of Liva Pharmaceuticals 57
Aug 24, 2018: Cadila Healthcare’s Biologics manufacturing facility successfully completes USFDA inspection 58
Jun 06, 2018: Cadila Healthcare: USFDA inspection of wholly-owned subsidiary, Alidac Pharmaceuticals Ltd., located at SEZ, Ahmedabad 59
Mar 28, 2018: Cadila Healthcare announces successfully completion of USFDA inspection at Topical facility 60
Feb 09, 2018: Cadila Healthcare’s Moraiya facility successfully completes USFDA inspection 61
Jan 19, 2018: Cadila Healthcare Announces Completion Of USFDA Inspection At Dabhasa, India Facility 62
Sep 07, 2017: Cadila Healthcare’s Moraiya facility successfully completes USFDA inspection 63
Aug 29, 2017: Zydus receives EIR Report for Manufacturing Facility at the Pharma SEZ at Ahmedabad 64
Jun 21, 2017: Zydus receives EIR Report for Moraiya Manufacturing Facility 65
Apr 07, 2017: Cadila Healthcare Provides Update on US FDA Inspection at Changodar Manufacturing Facility 66
Feb 16, 2017: Cadila Healthcare Provides Update On USFDA Inspection Of Moraiya Facility 67
Product News 68
Nov 29, 2017: New diagnostic kits developed to detect rare and neglected infectious diseases 68
Clinical Trials 69
Nov 20, 2017: Zydus Oral Anemia Developmental Candidate, ZYAN1 Named as Desidustat by WHO 69
Jul 05, 2017: Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD 70
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cadila Healthcare Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 14
Zydus Healthcare Acquires Six Brands from Merck 15
Zydus Cadila Healthcare Acquires Rights to Melgain from Issar Pharma 16
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 17
Zydus Cadila Healthcare to Acquire Actibile from Albert David for USD8.2 Million 18
Sentynl Therapeutics Acquires Abstral from Galena Biopharma 19
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 20
Zydus Cadila Healthcare to Enter into Agreement with Medicure International 22
Cadila Healthcare Enters into Agreement with Pharm Aid 23
Zydus Cadila Healthcare Enters into Agreement with Medicines for Malaria Venture 24
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 25
Zydus Cadila and Eczacibasi Enter into Agreement 26
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27
Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 28
IDRI And Zydus Cadila Healthcare Enter Into Agreement To Develop Vaccine Candidate For Visceral Leishmaniasis 30
Zydus Cadila On The Lookout For Partners To Market New Chemical Entity, Lipaglyn 31
Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 32
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 33
Zydus Cadila Healthcare Enters into Licensing Agreement with Neovii Biotech 34
Zydus Cadila Healthcare Enters into Licensing Agreement with Medicines Patent Pool 35
Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 36
Cadila Healthcare to Raise Funds in Public Offering of Securities 37
Zydus Healthcare to Acquire India Human Formulations Undertaking from Cadila Healthcare for USD10.2 Million 38
Cadila Healthcare Acquires 51% Stake in Windlas Healthcare for USD22.5 Million 39
Zydus Cadila Healthcare Acquires Sentynl Therapeutics for USD171 Million 40
Zydus Cadila Healthcare To Sell Nippon Universal Pharma 41
Cadila Healthcare Ltd, Key Competitors 42
Cadila Healthcare Ltd, Key Employees 43
Cadila Healthcare Ltd, Other Locations 44
Cadila Healthcare Ltd, Subsidiaries 44
Cadila Healthcare Ltd, Joint Venture 46

List of Figures
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cadila Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cadila Healthcare Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Cadila Healthcare Ltd (CADILAHC)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hitachi Metals, Ltd.：企業の戦略・SWOT・財務情報
    Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • The Royal Bank Of Scotland Group Plc
    The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report Summary The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Janssen Biotech, Inc.：企業のM&A・事業提携・投資動向
    Janssen Biotech, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Janssen Biotech, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • KS Energy Ltd (578)：企業の財務・戦略的SWOT分析
    KS Energy Ltd (578) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Firestone Diamonds Plc：企業の戦略・SWOT・財務分析
    Firestone Diamonds Plc - Strategy, SWOT and Corporate Finance Report Summary Firestone Diamonds Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Schreiber Foods, Inc.：企業の戦略・SWOT・財務情報
    Schreiber Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary Schreiber Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Combined Motor Holdings Ltd.：戦略・SWOT・企業財務分析
    Combined Motor Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Combined Motor Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • PharmaEssentia Corp (6446)-製薬・医療分野：企業M&A・提携分析
    Summary PharmaEssentia Corp (PharmaEssentia) is a research and development company that develops therapeutic products for the treatment of human diseases. The company’s pipeline product include P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. I …
  • Akcea Therapeutics Inc (AKCA)：製薬・医療：M&Aディール及び事業提携情報
    Summary Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc, is a developer and commercializer of drugs to treat patients with cardiometabolic diseases caused by lipid disorders. The company’s drugs are designed based on advanced antisense technology. Its pipeline …
  • Inception Sciences Inc-製薬・医療分野：企業M&A・提携分析
    Summary Inception Sciences Inc (Inception Sciences) is a pharmaceutical company that offers drug discovery incubators. The company develops new companies in partnership with academic researchers and biopharmaceutical companies. It develops drugs for various indications such as fibrotic diseases, onc …
  • Kawasumi Laboratories Inc (7703)：企業の財務・戦略的SWOT分析
    Summary Kawasumi Laboratories Inc (Kawasumi) is a medical device company that manufactures and distributes disposable blood collection and transfusion sets. The company’s product portfolio includes hemodialysis, plasmapheresis, blood banking and transfusion, infusion therapy, andendovascular repair …
  • Internet Initiative Japan Inc (3774)：企業の財務・戦略的SWOT分析
    Internet Initiative Japan Inc (3774) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Pacific Edge Ltd (PEB)：企業の財務・戦略的SWOT分析
    Summary Pacific Edge Ltd (PEB) is a diagnostics company that develops, discovers, and commercializes diagnostic tests for the early detection and monitoring of cancer. It offers lead products such as Cxbladder, a non-invasive laboratory test for the detection of bladder cancer. It also develops Cxco …
  • Lexmark International Inc：企業の戦略的SWOT分析
    Lexmark International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Zuger Kantonalbank AG：企業の戦略・SWOT・財務分析
    Zuger Kantonalbank AG - Strategy, SWOT and Corporate Finance Report Summary Zuger Kantonalbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Qualcomm Incorporated (QCOM)：企業の財務・戦略的SWOT分析
    Qualcomm Incorporated (QCOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Hanwha Q CELLS Co Ltd (HQCL)：電力：M&Aディール及び事業提携情報
    Summary Hanwha Q CELLS Co Ltd (Q CELLS) is a vertically integrated solar solution provider. It develops, manufactures and sells solar cells and modules. The company produces a wide range of PV cells and modules, and silicon ingots; and provides EPC services for the development and installation of gr …
  • BKW AG：企業の戦略・SWOT・財務分析
    BKW AG - Strategy, SWOT and Corporate Finance Report Summary BKW AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Vulcan Materials Company
    Vulcan Materials Company - Strategy, SWOT and Corporate Finance Report Summary Vulcan Materials Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Xcel Energy Inc (XEL)：企業の財務・戦略的SWOT分析
    Xcel Energy Inc (XEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆